Detalhe da pesquisa
1.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
2.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
3.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
4.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608562
5.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
; 98(10): E281-E284, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515433
6.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
7.
Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency.
Mycoses
; 66(12): 1029-1034, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550272
8.
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
; 97(12): 1560-1567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087091
9.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Acta Haematol
; 145(5): 529-536, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717939
10.
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
Cancer
; 127(19): 3552-3565, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161603
11.
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Br J Haematol
; 195(3): 378-387, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34340254
12.
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Am J Hematol
; 95(11): 1399-1420, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32744763
13.
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Hematol Oncol
; 37(1): 96-102, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30153704
14.
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
Am J Hematol
; 98(4): E91-E94, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36661399
15.
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Am J Hematol
; 96(7): E246-E249, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811786
16.
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
Am J Hematol
; 95(12): E326-E329, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886803
17.
Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery.
Nanotechnology
; 25(44): 445101, 2014 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25302488
18.
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome.
Clin Lymphoma Myeloma Leuk
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38777652
19.
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Cancer Med
; 13(5): e7093, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497538
20.
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.
Leuk Res
; 142: 107518, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744144